IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis.
OBJECTIVE: To test the hypothesis that patients with amyotrophic lateral sclerosis (ALS) inheriting the common interleukin 6 receptor (IL6R) coding variant (Asp
METHODS: An observational, case-control study of paired serum and CSF of 47 patients with ALS, 46 healthy, and 23 neurologic disease controls from the Northeastern ALS Consortium Biofluid Repository (cohort 1) was performed to determine serum levels of IL6, sIL6R, and soluble glycoprotein 130 and compared across groups and IL6R genotype. Clinical data regarding disease progression from a separate cohort of 35 patients with ALS from the Wake Forest ALS Center (cohort 2) were used to determine change in ALSFRS-R scores by genotype.
RESULTS: Patients with ALS had increased CSF IL6 levels compared with healthy (
CONCLUSIONS: Theses results suggest that for individuals inheriting the IL6R C allele, the cytokine exerts a disease- and location-specific role in ALS. Follow-up, prospective studies are necessary, as this subgroup of patients may be identified as ideally responsive to IL6 receptor-blocking therapies.
Neurol Neuroimmunol Neuroinflamm
Digital Object Identifier (DOI)
Wosiski-Kuhn, Marlena; Robinson, Mac; Strupe, Jane; Arounleut, Phonepasong; Martin, Matthew; Caress, James; Cartwright, Michael; Bowser, Robert; Cudkowicz, Merit; Langefeld, Carl; Hawkins, Gregory A; and Milligan, Carol, "IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis." (2019). Translational Neuroscience. 476.